Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 4:12:239-49.
doi: 10.2147/VHRM.S83088. eCollection 2016.

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Holly E Gurgle  1 , Karen White  1 , Carrie McAdam-Marx  1
Affiliations
Review

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Holly E Gurgle et al. Vasc Health Risk Manag. .

Abstract

Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient.

Keywords: A1c; GLP-1 receptor agonist; SGLT2 inhibitor; adverse effect; type 2 diabetes mellitus; weight loss.

PubMed Disclaimer

Figures

Figure1
Figure1
Flow diagram of GLP-1 study selection. Abbreviations: GLP-1RA, glucagon-like peptide-1 receptor agonists; RCT, randomized controlled trial; GLP-1, glucagon-like peptide-1.
Figure 2
Figure 2
Flow diagram of SGLT2-I study selection. Abbreviations: SGLT2-I, sodium–glucose cotransporter 2 inhibitors; RCT, randomized controlled trial;
See this image and copyright information in PMC

References

    1. CDC. Centers for Disease Control and Prevention . National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States. 2014.
    1. American Diabetes Association Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–S5. - PubMed
    1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87. - PMC - PubMed
    1. Byetta [prescribing information] Amylin Pharmaceuticals, Inc.; 2014. [Accessed October 1, 2015]. Available from: http://www.byettahcp.com.
    1. Victoza [prescribing information] Novo Nordisk; 2010. [Accessed October 1, 2015]. Available from: https://http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341l....

MeSH terms